⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

Official Title: Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)

Study ID: NCT01908101

Study Description

Brief Summary: This phase II trial studies how well eribulin mesylate works in treating patients with previously treated breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Detailed Description: PRIMARY OBJECTIVES: I. Progression free survival (PFS). SECONDARY OBJECTIVES: I. Frequency of alopecia with absence or decrease to \< 50%. II. Incidence of grade 3 and 4 neutropenia of \< 30%. III. Incidence of sensory neuropathy (all grades) to \< 25%. TERTIARY OBJECTIVES: I. Assess the role of circulating endothelial cell precursors (CEPs) and apoptotic circulating endothelial cells (CECs), in predicting early response to treatment. OUTLINE: Patients receive eribulin mesylate intravenously (IV) over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 1 year.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Katmai Oncology Group, Anchorage, Alaska, United States

Providence Alaska Medical Center, Anchorage, Alaska, United States

The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States

Bozeman Deaconess Hospital, Bozeman, Montana, United States

Bend Memorial Clinic, Bend, Oregon, United States

Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States

Skagit Valley Hospital, Mount Vernon, Washington, United States

Olympic Medical Center, Port Angeles, Washington, United States

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Group Health Cooperative-Seattle, Seattle, Washington, United States

MultiCare Tacoma General Hospital, Tacoma, Washington, United States

Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States

Contact Details

Name: Hannah Linden

Affiliation: Fred Hutch/University of Washington Cancer Consortium

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: